ABCC8 p.Gly716Asp
[switch to full view]Comments [show]
None has been submitted yet.
PMID: 21536946
[PubMed]
Macmullen CM et al: "Diazoxide-unresponsive congenital hyperinsulinism in children with dominant mutations of the beta-cell sulfonylurea receptor SUR1."
No.
Sentence
Comment
120
Two additional case subjects, with the V715G and G716D mutations, may also be de novo mutations; however, DNA was available on only one of the parents for genetic testing.
X
ABCC8 p.Gly716Asp 21536946:120:49
status: NEW148 Parent of origin Family 1 II-1 LGA 1 No Diffuse Q474R De novo Family 2 II-1 LGA 1 No Diffuse A478D Maternal Family 2 II-2 AGA 1 No Diffuse A478D Maternal Family 3 II-1 AGA 1 No Diffuse V715A Maternal Family 3 II-2 LGA 1 No No surgery V715A Maternal Family 4 II-1 LGA 1 No No surgery V715G Not maternal Family 5 II-1 LGA 1 No Diffuse V715G De novo Family 6 II-1 LGA 42 No Diffuse V715G De novo Family 7 II-1 LGA 5 No Diffuse G716D Not maternal Family 8 II-1 AGA 3 No Diffuse T888P De novo Family 9 II-1 AGA 2 No Diffuse G1384E De novo Family 10 II-1 LGA 1 No Diffuse S1387F De novo Family 11 II-1 LGA 1 No Diffuse S1387Y De novo Family 12 II-1 LGA 1 No Diffuse S1389Y De novo Family 13 II-1 SGA 180 No Diffuse A1458T Paternal Family 14 II-1 LGA 88 No Diffuse Q1459H De novo Family 15 II-1 AGA 167 No Diffuse E1517K Maternal Dominant diazoxide-unresponsive (n = 17) 65% LGA median 1 day range (1-180 days) 100% no Diffuse 5 of 17 maternal 1 of 17 paternal 9 of 17 de novo 2 of 17 not maternal Dominant diazoxide-responsive (n = 13) 77% LGA median 30 days range (1-1,215 days) 100% yes Diffuse 5 of 13 maternal 4 of 13 paternal 4 of 13 de novo Recessive (n = 48) 87% LGA median 1 day range (1-9 days) 100% no Diffuse 48 of 48 biallelic LGA, AGA, SGA 5 large, appropriate, small for gestational age.
X
ABCC8 p.Gly716Asp 21536946:148:424
status: NEW189 The important distinction between dominant and recessive missense mutations of the ABCC8 gene that cause hyperinsulinism appears to be whether they produce SUR1 subunits that can combine with Kir6.2 and then be trafficked to the TABLE 2 Mutant protein biogenesis and activity Surface expression (% of wild-type channel level) MgADP stimulation (% current in 0.1 mmol/L ATP plus 0.5 mmol/L ADP) Diazoxide stimulation (% current in 0.1 mmol/L ATP plus 0.2 mmol/L diazoxide) Mutation 1) Q474R 119.12 6 13.87 3.16 6 1.34 (n = 3) 2.03 6 0.77 (n = 3) 2) A478D 83.67 6 5.33 0.69 6 0.27 (n = 6) 3.14 6 1.37 (n = 3) 3) V715A 83.00 6 5.29 0.53 6 0.28 (n = 3) 1.73 6 0.53 (n = 4) 4) V715G 96.33 6 3.18 0.28 6 0.16 (n = 3) 2.35 6 1.99 (n = 3) 5) G716D 66.67 6 5.24 2.39 6 1.90 (n = 6) 2.37 6 1.32 (n = 4) 6) T888P 54.33 6 5.33 0.38 6 0.30 (n = 3) 1.30 6 0.44 (n = 3) 7) G1384E 101.80 6 8.50 0.17 6 0.09 (n = 4) 1.64 6 0.49 (n = 4) 8) S1387F 83.91 6 5.30 0.84 6 0.17 (n = 4) 4.05 6 1.34 (n = 4) 9) S1387Y 83.13 6 5.38 2.46 6 0.96 (n = 4) 2.44 6 0.42 (n = 4) 10) S1389Y 70.00 6 7.81 1.26 6 0.73 (n = 4) 1.65 + 0.63 (n = 3) 11) A1458T 94.33 6 10.48 0.52 6 0.21 (n = 3) 1.06 6 0.37 (n = 3) 12) Q1459H 91.00 6 2.31 0.69 6 0.39 (n = 3) 1.32 6 0.29 (n = 3) 13) E1517K 72.88 6 5.85 1.73 6 0.39 (n = 3) 1.96 6 0.55 (n = 4) Mean of dominant diazoxide-unresponsive SUR1 mutations 84.6 6 4.64 (n = 13) 1.42 6 0.35 (n = 13)* 1.83 6 0.18 (n = 13)† Mean of dominant diazoxide-responsive SUR1 mutations 93.68 6 5.07 (n = 10) 14.52 6 5.15 (n = 10) 18.33 6 6.06 (n = 10) Wild type 100 61.19 6 5.53 (n = 11) 77.8 6 2.2 (n = 9) Data are means 6 SE.
X
ABCC8 p.Gly716Asp 21536946:189:734
status: NEW
PMID: 20685672
[PubMed]
Bellanne-Chantelot C et al: "ABCC8 and KCNJ11 molecular spectrum of 109 patients with diazoxide-unresponsive congenital hyperinsulinism."
No.
Sentence
Comment
107
1 DH c-htz This report ABCC8 Exon 16 c.2124_2127delGACT p.Thr709X 1 FH This report ABCC8 Exon 16 c.2147G/A p.Gly716Asp 1 DPET htzm This report ABCC8 Exon 16 c.2153delG p.Gly718fs 1 DH htzP This report ABCC8 Exon 20 c.2425C/T p.Gln809X 1 DH c-htz Damaj et al, 200845 ABCC8 Exon 20 c.2473G/A p.Glu825Lys 1 DPET htzP This report ABCC8 Exon 22 c.2560-?_2697+?del p.Asp854_Trp899del46 1 DH c-htz This report ABCC8 Exon 22 c.2581G/C p.Asp861His 1 DPVS c-htz This report ABCC8 Exon 22 c.2669A/C p.Lys890Thr 1 DH htzP Flanagan et al, 200817 ABCC8 Exon 22 c.2672T/C p.Leu891Pro 1 DH htznovo This report ABCC8 Exon 23 c.2702T/C p.Ile901Thr 2 DH, DPET c-htz This report ABCC8 Exon 23 c.2784G/A p.Trp928X 1 FH This report ABCC8 Exon 23 c.2803C/T p.Gln935X 1 DPET c-htz This report ABCC8 Exon 24 c.2860C/T p.Gln954X 1 FH Flanagan et al, 200817 ABCC8 Intron 24 c.2924-9G/A p.?
X
ABCC8 p.Gly716Asp 20685672:107:109
status: NEW119 There is strong evidence that the identified mutation Gly716Asp is pathogenic: (1) it is located in the first nucleotide binding domain, (2) the same residue was reported to be altered (Gly716Val) in a homozygous recessive form of CHI resistant to diazoxide30 and (3) the functional study of Gly716Val showed a reduced surface expression of the mutant channel.31 Among the eight paternally inherited cases, no clinical symptom was reported in the fathers at the time of the child`s diagnosis.
X
ABCC8 p.Gly716Asp 20685672:119:54
status: NEW110 1 DH c-htz This report ABCC8 Exon 16 c.2124_2127delGACT p.Thr709X 1 FH This report ABCC8 Exon 16 c.2147G/A p.Gly716Asp 1 DPET htzm This report ABCC8 Exon 16 c.2153delG p.Gly718fs 1 DH htzP This report ABCC8 Exon 20 c.2425C/T p.Gln809X 1 DH c-htz Damaj et al, 200845 ABCC8 Exon 20 c.2473G/A p.Glu825Lys 1 DPET htzP This report ABCC8 Exon 22 c.2560-?_2697+?del p.Asp854_Trp899del46 1 DH c-htz This report ABCC8 Exon 22 c.2581G/C p.Asp861His 1 DPVS c-htz This report ABCC8 Exon 22 c.2669A/C p.Lys890Thr 1 DH htzP Flanagan et al, 200817 ABCC8 Exon 22 c.2672T/C p.Leu891Pro 1 DH htznovo This report ABCC8 Exon 23 c.2702T/C p.Ile901Thr 2 DH, DPET c-htz This report ABCC8 Exon 23 c.2784G/A p.Trp928X 1 FH This report ABCC8 Exon 23 c.2803C/T p.Gln935X 1 DPET c-htz This report ABCC8 Exon 24 c.2860C/T p.Gln954X 1 FH Flanagan et al, 200817 ABCC8 Intron 24 c.2924-9G/A p.?
X
ABCC8 p.Gly716Asp 20685672:110:109
status: NEW123 There is strong evidence that the identified mutation Gly716Asp is pathogenic: (1) it is located in the first nucleotide binding domain, (2) the same residue was reported to be altered (Gly716Val) in a homozygous recessive form of CHI resistant to diazoxide30 and (3) the functional study of Gly716Val showed a reduced surface expression of the mutant channel.31 Among the eight paternally inherited cases, no clinical symptom was reported in the fathers at the time of the child`s diagnosis.
X
ABCC8 p.Gly716Asp 20685672:123:54
status: NEW